Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share.ASP Isotopes
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday.Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-
Express News | Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
TD Cowen analyst Tyler Van Buren maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright analyst Yi Chen maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 24.
Express News | HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target
EyePoint Pharmaceuticals To Highlight DURAVYUTM Clinical And Regulatory Developments At R&D Day 2024
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 –– Positive twelv
EyePoint Pharmaceuticals (NASDAQ:EYPT Shareholders Incur Further Losses as Stock Declines 12% This Week, Taking Five-year Losses to 51%
Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big losses. For example the EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) share price drop
Express News | Cantor Fitzgerald Reiterates Overweight on EyePoint Pharmaceuticals
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
Mizuho Securities analyst Graig Suvannavejh maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Capital One Financial analyst Tim Chiang maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success ra
EyePoint Pharmaceuticals(EYPT.US) Director Sells US$119.7K in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ Director GUYER DAVID R sold 11,625 shares of common stock on Jun 3, 2024 at an average price of $10.2972 for a total value of $119.7K.Source: Announcement What is s
EyePoint Pharmaceuticals Is Maintained at Overweight by JP Morgan
EyePoint Pharmaceuticals Is Maintained at Overweight by JP Morgan
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
EyePoint Pharmaceuticals (EYPT) has an average rating of Buy and price targets ranging from $28 to $68, according to analysts polled by Capital IQ.
Express News | EyePoint Pharmaceuticals Inc : JP Morgan Cuts Target Price to $32 From $35
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Phase 3 Trials and FDA Alignment
Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a Year Ago Would Have Delivered You a 91% Gain
Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals(EYPT.US) Director Sells US$147.04K in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ Director GUYER DAVID R sold 11,625 shares of common stock on May 14, 2024 at an average price of $12.649 for a total value of $147.04K.Source: Announcement What is
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies c